NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.940
-0.130 (-6.28%)
At close: Jun 1, 2026, 4:00 PM EDT
1.988
+0.048 (2.48%)
After-hours: Jun 1, 2026, 5:01 PM EDT
NervGen Pharma Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, NervGen Pharma stock has a consensus rating of "Buy" and an average price target of $11.21. The average 1-year stock price forecast is 477.84% higher than the current stock price, while the lowest is $5.03 (+159.28%) and the highest is $18 (+827.84%).
Price Target: $11.21 (+477.84%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 28, 2026.
Analyst Ratings
The average analyst rating for NervGen Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 3 | 2 |
| Buy | 3 | 3 | 2 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 4 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $6 | Buy | Maintains | $6 | +209.28% | Apr 28, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $18 | Buy | Reiterates | $18 | +827.84% | Apr 27, 2026 |
| Lucid Capital | Lucid Capital | Buy Initiates $18 | Buy | Initiates | $18 | +827.84% | Apr 15, 2026 |
| Research Capital | Research Capital | Buy Maintains $5.5 | Buy | Maintains | $5.5 | +183.51% | Apr 10, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $10 → $12 | Buy | Reiterates | $10 → $12 | +518.56% | Apr 8, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.38
from -0.61
EPS Next Year
-0.50
from -0.38
Financial currency is CAD.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.32 | ||
| Avg | -0.38 | ||
| Low | -0.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.